BioTelemetry Inc (BEAT) Position Reduced by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. reduced its holdings in shares of BioTelemetry Inc (NASDAQ:BEAT) by 35.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 31,125 shares of the medical research company’s stock after selling 16,928 shares during the quarter. Dana Investment Advisors Inc. owned approximately 0.09% of BioTelemetry worth $1,859,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Meeder Asset Management Inc. bought a new stake in shares of BioTelemetry in the fourth quarter valued at $108,000. Loomis Sayles & Co. L P bought a new stake in shares of BioTelemetry in the third quarter valued at $23,211,000. Federated Investors Inc. PA raised its stake in shares of BioTelemetry by 8,359.7% in the third quarter. Federated Investors Inc. PA now owns 44,667 shares of the medical research company’s stock valued at $2,879,000 after buying an additional 44,139 shares during the period. Logan Capital Management Inc. raised its stake in shares of BioTelemetry by 5.4% in the third quarter. Logan Capital Management Inc. now owns 52,524 shares of the medical research company’s stock valued at $3,385,000 after buying an additional 2,705 shares during the period. Finally, Vanguard Group Inc raised its stake in shares of BioTelemetry by 2.8% in the third quarter. Vanguard Group Inc now owns 1,900,117 shares of the medical research company’s stock valued at $122,462,000 after buying an additional 52,363 shares during the period. Institutional investors and hedge funds own 89.73% of the company’s stock.

In other news, VP Heather C. Getz sold 10,590 shares of BioTelemetry stock in a transaction on Friday, February 1st. The stock was sold at an average price of $70.41, for a total value of $745,641.90. Following the completion of the transaction, the vice president now directly owns 80,661 shares in the company, valued at $5,679,341.01. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Heather C. Getz sold 8,236 shares of BioTelemetry stock in a transaction on Thursday, January 17th. The shares were sold at an average price of $70.01, for a total value of $576,602.36. Following the completion of the transaction, the vice president now owns 88,797 shares of the company’s stock, valued at $6,216,677.97. The disclosure for this sale can be found here. Over the last quarter, insiders sold 177,198 shares of company stock valued at $12,419,736. 8.30% of the stock is owned by company insiders.

Shares of NASDAQ BEAT opened at $67.54 on Friday. The firm has a market capitalization of $2.27 billion, a PE ratio of 34.81 and a beta of 1.47. BioTelemetry Inc has a fifty-two week low of $29.85 and a fifty-two week high of $80.92. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.96 and a quick ratio of 2.81.

BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Thursday, February 21st. The medical research company reported $0.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.13. The company had revenue of $103.60 million during the quarter, compared to analysts’ expectations of $102.84 million. BioTelemetry had a return on equity of 24.46% and a net margin of 10.72%. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 earnings per share. As a group, equities research analysts predict that BioTelemetry Inc will post 1.86 earnings per share for the current year.

Several brokerages have issued reports on BEAT. Zacks Investment Research lowered BioTelemetry from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. ValuEngine lowered BioTelemetry from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 23rd. BidaskClub lowered BioTelemetry from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 18th. Lake Street Capital set a $90.00 target price on BioTelemetry and gave the company a “buy” rating in a research note on Friday, February 22nd. Finally, Sidoti set a $95.00 target price on BioTelemetry and gave the company a “buy” rating in a research note on Tuesday, February 5th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $75.67.

COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2019/03/17/biotelemetry-inc-beat-position-reduced-by-dana-investment-advisors-inc.html.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

See Also: Growth Stocks

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply